Sunshine Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sunshine Biopharma.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Biotechs Gewinnwachstum	27.1%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	20 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Mar 14

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Jan 29

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sep 12

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Sunshine Biopharma jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:SBFM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2024	44	N/A	N/A	N/A	1
6/30/2024	30	-4	-12	-11	N/A
3/31/2024	27	-4	-11	-10	N/A
12/31/2023	24	-5	-10	-9	N/A
9/30/2023	20	-27	-9	-8	N/A
6/30/2023	15	-28	-10	-9	N/A
3/31/2023	9	-27	-6	-6	N/A
12/31/2022	4	-27	-6	-5	N/A
9/30/2022	0	-3	-3	-3	N/A
6/30/2022	0	-5	-3	-3	N/A
3/31/2022	0	-7	-3	-3	N/A
12/31/2021	0	-12	-2	-2	N/A
9/30/2021	0	-14	-2	-2	N/A
6/30/2021	0	-11	-1	-1	N/A
3/31/2021	0	-9	-1	-1	N/A
12/31/2020	0	-3	-1	-1	N/A
9/30/2020	0	-2	0	0	N/A
6/30/2020	0	-2	0	0	N/A
3/31/2020	0	-1	0	0	N/A
12/31/2019	0	-1	0	0	N/A
9/30/2019	0	-1	0	0	N/A
6/30/2019	0	-2	-1	-1	N/A
3/31/2019	0	-2	-1	-1	N/A
12/31/2018	N/A	-2	-1	-1	N/A
9/30/2018	N/A	-2	-1	-1	N/A
6/30/2018	N/A	-1	-1	-1	N/A
3/31/2018	0	-1	N/A	-1	N/A
12/31/2017	N/A	-1	N/A	-1	N/A
9/30/2017	N/A	-2	N/A	0	N/A
6/30/2017	N/A	-3	N/A	0	N/A
3/31/2017	N/A	-3	N/A	0	N/A
12/31/2016	N/A	-3	N/A	0	N/A
9/30/2016	N/A	-3	N/A	-1	N/A
6/30/2016	N/A	-2	N/A	-1	N/A
3/31/2016	0	-2	N/A	-1	N/A
12/31/2015	0	-2	N/A	-1	N/A
9/30/2015	0	-1	N/A	-1	N/A
6/30/2015	0	-1	N/A	-1	N/A
3/31/2015	N/A	-2	N/A	-1	N/A
12/31/2014	N/A	-2	N/A	-1	N/A
9/30/2014	N/A	-2	N/A	0	N/A
6/30/2014	N/A	-2	N/A	0	N/A
3/31/2014	N/A	-2	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if SBFM's forecast earnings growth is above the savings rate (2.5%).

Ertrag vs. Markt: Insufficient data to determine if SBFM's earnings are forecast to grow faster than the US market

Hohe Wachstumserträge: Insufficient data to determine if SBFM's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if SBFM's revenue is forecast to grow faster than the US market.

Hohe Wachstumseinnahmen: Insufficient data to determine if SBFM's revenue is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if SBFM's Return on Equity is forecast to be high in 3 years time

Sunshine Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Sunshine Biopharma, Inc., Annual General Meeting, Dec 10, 2024

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Sunshine Biopharma Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101

Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Sunshine Biopharma Announces Update on Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Share price stability

Sunshine Biopharma, Inc. Announces Executive Changes

Sunshine Biopharma, Inc. Announces Executive Changes

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Third quarter 2023 earnings: EPS exceeds analyst expectations

Sunshine Biopharma, Inc., Annual General Meeting, Dec 07, 2023

Sunshine Biopharma Receives 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Sunshine Biopharma, Inc. announced that it has received CAD 5 million in funding

First quarter 2023 earnings released: US$0.077 loss per share (vs US$0.23 loss in 1Q 2022)

Full year 2022 earnings released: US$1.76 loss per share (vs US$4.76 loss in FY 2021)

Sunshine Biopharma, Inc. (NasdaqCM:SBFM) announces an Equity Buyback for $2 million worth of its shares.

Sunshine Biopharma Receives Non-Compliance Notice From Nasdaq

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$1.59 loss in 3Q 2021)

Sunshine Biopharma, Inc. (NasdaqCM:SBFM) completed the acquisition of Nora Pharma Inc. from Malek Chamoun.

Sunshine Biopharma acquires Nora Pharma for C$30M

We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Second quarter 2022 earnings released: US$0.034 loss per share (vs US$1.20 loss in 2Q 2021)

Sunshine Biopharma reports 1H results

First quarter 2022 earnings released: US$0.23 loss per share (vs US$2.82 loss in 1Q 2021)

Sunshine Biopharma, Inc. Files Patent Application Announces mRNA Molecules

Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs

Sunshine Biopharma, Inc.’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells

Less than half of directors are independent

Sunshine Biopharma Common Stock Deleted from Other OTC

Sunshine Biopharma Mice Study for Covid-19 Treatment Progressing as Planned

Sunshine Biopharma, Inc.’s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer Types

Sunshine Biopharma, Inc. announced that it has received $0.5 million in funding from RB Capital Partners, Inc.

Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a and Initiates QA/QC Testing

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken